Third-party tested for purity and potency
The FDA removed BPC-157 from the list of substances that can be used by compounding pharmacies specifically, its no longer on the 503A or 503B bulk drug substance lists that allow compounders to make non-FDA-approved drugs legally
Patients should report any mood changes, increased anxiety, or depressive symptoms promptly
Common side effects are mild and include injection site reactions (redness, irritation), temporary water retention, tingling or numbness in the extremities, mild headache, and occasional flushing
Whether you're using long-acting IGF-1 LR3 or fast-acting IGF-1 DES , the peptides ability to stimulate hypertrophy and accelerate tissue repair is unmatched
This small difference is nowhere near enough to affect overall effectiveness in the liposomal vs sublingual NAD+ debate